

## **Avalanche Biotechnologies Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 02-May-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 9

    Phase 2 Clinical..... 10

    Discovery..... 15

[Return to Table of Contents](#)

# Avalanche Biotechnologies Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Avalanche Biotechnologies Inc
<b>Parent Company Name</b>	Avalanche Biotechnologies Inc
<b>Website</b>	http://www.avalanchebiotech.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	6
<b>Number of Inactive Drugs</b>	0
<b>Number of Patents as Owner</b>	3
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	7
<b>Key Indications</b>	Wet age related macular degeneration,Color vision defect,Diabetic macular edema,Glaucoma,Retinal venous occlusion,Retinoschisis,Unidentified indication,Diabetic retinopathy,Retinitis pigmentosa,Stargardt disease
<b>Key Target-based Actions</b>	RS1 gene modulator,VEGF-1 receptor antagonist,Angiostatin gene modulator,CNTF gene modulator,FLT1 gene modulator,GDNF gene modulator,RPE65 gene modulator,TIMP3 gene modulator,VEGF receptor
<b>Key Technologies</b>	Virus recombinant,Biological therapeutic,Parenteral formulation unspecified,Injectable formulation,Ophthalmic formulation,Small molecule therapeutic,Gene transfer system viral,Gene expression regulation,Monoclonal

## COMPANY PROFILE

### SUMMARY

Avalanche Biotechnologies is developing technologies and products for the sustained delivery of therapeutic proteins in patients with ocular diseases, with a focus on wet AMD.

### COMPANY LOCATION

In September 2011, the company opened new office and research facilities in San Francisco, CA.

### FINANCIAL

In January 2015, the company filed a registration statement on Form S-1/A with the Securities and Exchange Commission relating to a proposed public offering of 2,000,000 common stock shares. The offering was expected to consist of 1,762,500 shares by Avalanche and 237,500 shares to be offered by existing stockholders. At that time, the underwriters were granted a 30-day option to purchase up to an additional 300,000 shares from the selling shareholders and Avalanche, and agreed for lock-up agreements for a period of 90 days following the follow-on offering; Later that month, the company priced the public offering of 2,399,457 shares of \$141.6 million of common stock, each at a price of \$59.00 per share. At that time, the underwriters were granted a 30-day option to purchase up to an additional 359,918 shares of common stock. The follow-on offering was expected to close on January 13, 2015, which was subjected to customary closing conditions.

By September 2014, the company had completed a \$10 million private placement of common stock to Regeneron Pharmaceuticals Inc.

In July 2014, the company priced its initial public offering of 6 million shares of its common stock, at \$17 each and planned to raise \$102 million. The underwriters were granted a 30-day option to purchase up to 0.9 million additional shares of common stock. The offering was expected to close on August 05, 2014. At that time, the company's common stock began trading on the NASDAQ Global Market under the ticker symbol "AAVL". By September 2014, the company had raised net proceeds of approximately \$106.5 million from the placement of 6.9 million shares of its common stock, which included the full exercise of the underwriters' over-allotment option.

In April 2014, the company raised \$55 million in a series B financing round.

[Return to Table of Contents](#)




In September 2012, the company completed a series A financing. In November 2013, Avalanche raised additional financing in a follow-on round consisting of both new and existing investors. The financing included both preferred stock and convertible debt.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	5	0	5
Unidentified indication	1	0	1
Cardiovascular disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	5

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Patent - Exclusive Rights	0	0	1	0	1
Drug - Funding	2	0	0	0	2
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	1	0	1	0	2
Technology - Delivery/Formulation	1	0	0	0	1

[Return to Table of Contents](#)



## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 1	0	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Ocular disease	3	0	3
Otorhinolaryngological disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)





## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia SNAPSHOT

<b>Drug Name</b>	VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia
<b>Key Synonyms</b>	
<b>Originator Company</b>	University of Western Australia
<b>Active Companies</b>	Avalanche Biotechnologies Inc;Lions Eye Institute of Western Australia Inc;University of Western Australia
<b>Inactive Companies</b>	Merck Sharp & Dohme Corp
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Diabetic macular edema;Wet age related macular degeneration;Retinal venous occlusion
<b>Target-based Actions</b>	VEGF-1 receptor antagonist
<b>Other Actions</b>	Ophthalmological agent;Ocular antineovascularisation agent;Adeno-associated virus based gene therapy
<b>Technologies</b>	Sustained release formulation;Injectable formulation;Virus recombinant;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified
<b>Last Change Date</b>	06-Mar-2015

### VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia DEVELOPMENT PROFILE

#### SUMMARY

Avalanche Biotechnologies, in collaboration with Lions Eye Institute of the University of Western Australia, is developing a sustained-release, subretinal formulation of AVA-101 (rAAV.sFLT-1), a recombinant adeno-associated virus (AAV)-based therapy delivering Flt-1 (VEGF-1 receptor antagonist), for the potential treatment of wet age-related macular degeneration (AMD) . Avalanche is also investigating the program for diabetic macular edema (DME) and retinal vein occlusion (RVO). In December 2011, a phase I/II trial began ; in May 2012, preliminary data were presented ; in May 2013, further data were presented. In July 2014, top-line phase IIa data was expected mid-2015, and an IND-filing was expected in the second half of 2015. In May 2014, it was stated that upon completion of the phase IIa trial, Regeneron would have a time-limited right of first negotiation for certain rights to AVA-101 .

Merck Sharpe & Dohme was originally developing the drug; however, by November 2011, rights were licensed to Avalanche.

### VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Wet age related macular degeneration	Australia	Phase 2 Clinical	14-Dec-2011
Lions Eye Institute of Western Australia Inc	Wet age related macular degeneration	Australia	Phase 2 Clinical	14-Dec-2011
University of Western Australia	Wet age related macular degeneration	Australia	Phase 2 Clinical	14-Dec-2011
Avalanche Biotechnologies Inc	Diabetic macular edema	US	Discovery	10-Sep-2012
Avalanche Biotechnologies Inc	Retinal venous occlusion	US	Discovery	08-Jul-2014
Merck Sharp & Dohme Corp	Wet age related macular degeneration	US	Discontinued	01-Nov-2011

### VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia DRUG NAMES

Names	Type
AVA-101	Research Code
rAAV.sFLT-1	Research Code
adenovirus-based therapy (wet AMD), Avalanche Biotechnologies/Lions Eye Institute	
VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia	

### VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Wet age related macular degeneration											
0	0	0	0	0	0	0	1	0	0	0	1

#### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

#### Phase Definitions

##### Phase 3 Clinical

[Return to Table of Contents](#)

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## VEGF-1 (Flt-1) receptor antagonist (adenovirus vector, wet AMD), Avalanche Biotechnologies/Lions Eye Institute/ University of Western Australia DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart




#### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Avalanche Biotechnologies Inc	2	0	1	0	3
Regeneron Pharmaceuticals Inc	0	0	1	0	1
Merck & Co Inc	0	0	0	1	1
University of Western Australia	0	1	0	0	1
Lions Eye Institute of Western Australia Inc	1	0	0	0	1
US Government	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	1	3
Drug - Funding	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Stanford University	1	0	1
Lions Eye Institute of Western Australia Inc	1	0	1
Avalanche Biotechnologies Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1

[Return to Table of Contents](#)

## AVA-322/AVA-323 (undisclosed indication), Avalanche

### AVA-322/AVA-323 (undisclosed indication), Avalanche SNAPSHOT

Drug Name	AVA-322/AVA-323 (undisclosed indication), Avalanche
Key Synonyms	
Originator Company	Avalanche Biotechnologies Inc
Active Companies	Avalanche Biotechnologies Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	
Other Actions	Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	09-Jul-2014

### AVA-322/AVA-323 (undisclosed indication), Avalanche DEVELOPMENT PROFILE

#### SUMMARY

Avalanche Biotechnologies is investigating a program including AVA-322 and AVA-323, for the potential treatment of an undisclosed indication. In July 2014, the program was in research, and IND-enabling studies were planned for 2015.

### AVA-322/AVA-323 (undisclosed indication), Avalanche DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Unidentified indication	US	Discovery	08-Jul-2014

### AVA-322/AVA-323 (undisclosed indication), Avalanche DRUG NAMES

Names	Type
AVA-322/AVA-323 (undisclosed indication), Avalanche	

[Return to Table of Contents](#)

## AVA-311

### AVA-311 SNAPSHOT

Drug Name	AVA-311
Key Synonyms	
Originator Company	Avalanche Biotechnologies Inc
Active Companies	Avalanche Biotechnologies Inc;Regeneron Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Retinoschisis
Target-based Actions	RS1 gene modulator
Other Actions	Adeno-associated virus based gene therapy;Ophthalmological agent
Technologies	Injectable formulation;Virus recombinant;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	08-Jul-2014

### AVA-311 DEVELOPMENT PROFILE

#### SUMMARY

Avalanche Biotechnologies in collaboration with Regeneron, is investigating an intravitreal formulation of AVA-311, an adeno-associated virus (AAV)-based gene therapy delivering RS1 gene, using Avalanche's directed evolution technology, for the potential treatment of juvenile X-linked retinoschisis (XLRS). In July 2014, the drug was in preclinical development.

### AVA-311 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Retinoschisis	US	Discovery	05-May-2014
Regeneron Pharmaceuticals Inc	Retinoschisis	US	Discovery	05-May-2014

### AVA-311 DRUG NAMES

Names	Type
AVA-311	Research Code



[Return to Table of Contents](#)



AVA-311 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Avalanche Biotechnologies Inc	1	0	0	0	1
Regeneron Pharmaceuticals Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

## Shh10.GDNF

### Shh10.GDNF SNAPSHOT

Drug Name	Shh10.GDNF
Key Synonyms	
Originator Company	Avalanche Biotechnologies Inc
Active Companies	Avalanche Biotechnologies Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Glaucoma
Target-based Actions	
Other Actions	Ophthalmological agent;Neuroprotectant;Antiglaucoma agent
Technologies	Virus recombinant;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	04-Aug-2014

### Shh10.GDNF DEVELOPMENT PROFILE

#### SUMMARY

Avalanche is investigating Shh-10.GDNF, a novel muLLer glia cell-specific adeno-associated viral vector expressing glial cell line-derived neurotrophic factor (GDNF), for the potential treatment of glaucoma. In May 2012, preclinical data were presented. In March 2013, development was ongoing.

### Shh10.GDNF DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Glaucoma	US	Discovery	08-May-2012


### Shh10.GDNF DRUG NAMES

Names	Type
Shh10.GDNF	Research Code
AAV-based therapy (glaucoma), Avalanche	

[Return to Table of Contents](#)

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Avalanche Biotechnologies Inc	1	0	0	0	1
US Government	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Avalanche Biotechnologies Inc	1	0	1
Stanford University	1	0	1
Lions Eye Institute of Western Australia Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	1

[Return to Table of Contents](#)

## AVA-201

### AVA-201 SNAPSHOT

Drug Name	AVA-201
Key Synonyms	
Originator Company	Avalanche Biotechnologies Inc
Active Companies	Avalanche Biotechnologies Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Wet age related macular degeneration
Target-based Actions	VEGF-1 receptor antagonist
Other Actions	Adeno-associated virus based gene therapy;Ophthalmological agent;Ocular antineovascularisation agent
Technologies	Injectable formulation;Virus recombinant;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified
Last Change Date	08-Jul-2014

### AVA-201 DEVELOPMENT PROFILE

#### SUMMARY

Avalanche Biotechnologies is investigating an intravitreal formulation of AVA-201, a recombinant adeno-associated virus (AAV)-based gene therapy delivering sFlt-1 (VEGF-1 receptor antagonist) using the company's next-generation AAV vector delivery technology, for the potential prevention of wet age-related macular degeneration (AMD). In July 2014, the drug was in research, and IND-enabling studies were planned for 2015.

### AVA-201 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Wet age related macular degeneration	US	Discovery	08-Jul-2014

### AVA-201 DRUG NAMES

Names	Type
AVA-201	Research Code

[Return to Table of Contents](#)





## adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies

### adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies SNAPSHOT

Drug Name	adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies
Key Synonyms	
Originator Company	University of Washington
Active Companies	Avalanche Biotechnologies Inc;University of Washington
Inactive Companies	
Highest Status	Discovery
Active Indications	Color vision defect
Target-based Actions	
Other Actions	Adeno-associated virus based gene therapy;Unspecified drug target
Technologies	Biological therapeutic
Last Change Date	26-Mar-2015

### adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies DEVELOPMENT PROFILE

#### SUMMARY

University of Washington and licensee Avalanche Biotechnologies are investigating adeno-associated virus (AAV) vector based gene therapies, applying Avalanche's Ocular BioFactory technology, for the potential treatment of color vision deficiency. By October 2009, preclinical studies had been conducted.

### adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Avalanche Biotechnologies Inc	Color vision defect	US	Discovery	25-Mar-2015
University of Washington	Color vision defect	US	Discovery	08-Oct-2009

### adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies DRUG NAMES


Names	Type
adeno-associated virus (AVV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies	

[Return to Table of Contents](#)

adeno-associated virus (AAV) vector based gene therapy (color vision deficiency), University of Washington/ Avalanche Biotechnologies
 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
University of Washington	1	0	0	0	1
Avalanche Biotechnologies Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	1	0	1

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)